Janux Therapeutics (NASDAQ:JANX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Janux Therapeutics (NASDAQ:JANX) announced its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13, Zacks reports. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Janux Therapeutics Stock Performance

JANX traded up $0.31 during midday trading on Friday, hitting $32.32. The stock had a trading volume of 460,406 shares, compared to its average volume of 1,011,229. The company has a market cap of $1.70 billion, a P/E ratio of -27.60 and a beta of 3.16. The business has a fifty day moving average of $44.22 and a 200 day moving average of $47.83. Janux Therapeutics has a 1 year low of $31.69 and a 1 year high of $71.71.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total value of $1,404,750.00. Following the sale, the chief executive officer now directly owns 217,054 shares in the company, valued at approximately $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,668 shares of company stock worth $3,582,515 over the last three months. Company insiders own 29.40% of the company’s stock.

Analyst Upgrades and Downgrades

JANX has been the topic of several research reports. BTIG Research upped their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Stifel Nicolaus boosted their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Finally, HC Wainwright raised their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $90.10.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.